Search

Displaying results 4681 - 4690 of 10000 in total
  1. Drug

    KAI-1455

    go.drugbank.com/drugs/DB06064
    Experimental

    In preclinical studies, KAI-1455 showed a dramatic reduction in infarct size when delivered prior to the ischemic insult. … Several studies have demonstrated that epsilon PKC plays a key role in cytoprotection during periods of ischemia.

  2. Drug

    Nickel cation

    go.drugbank.com/drugs/DB14204
    Investigational

    Synonyms: Nickel(II) ion, Nickel ion(2+)Mixtures: BIOGROW MIN
  3. Drug

    Omega-6 fatty acids

    go.drugbank.com/drugs/DB13168
    InvestigationalNutraceutical

    Cells involved in the inflammatory response are typically rich in the n-6 fatty acid arachidonic acid, as generally, eicosanoids derived from n-6 PUFA are pro-inflammatory. … Omega-6 fatty acids are polyunsaturated fatty acids with a final carbon-carbon double bond in the n-6 position, that is, the sixth bond, counting from the methyl end.

    Synonyms: n-6 fatty acids
  4. Drug

    Ubenimex

    go.drugbank.com/drugs/DB03424
    Investigational

    It is being studied for use in the treatment of acute myelocytic leukemia. … Ubenimex (also known as bestatin) is a competitive protease inhibitor. It is an inhibitor of aminopeptidase B, leukotriene A4 hydrolase, aminopeptidase N.

  5. Drug

    Dihydrofolic Acid

    go.drugbank.com/drugs/DB02015
    Investigational

    Mixtures: EnLyte Extra-LN
  6. Drug

    IPH 2101

    go.drugbank.com/drugs/DB06049
    Investigational

    IPH-2101 (NN-1975), a fully human monoclonal antibody developed for patients with acute myeloid leukemia.

  7. Drug

    Methyl salicylate 2-ethylbutyrate

    go.drugbank.com/drugs/DB14130
    Investigational

    Mixtures: Thera Derm Roll On
  8. Drug

    FP0011

    go.drugbank.com/drugs/DB05090
    Experimental

    FP0011 is a small molecule antiglutamatergic compound with symptomatic and disease modifying effects in a variety of neurological disorders (amyotrophic lateral sclerosis and Parkinson's disease). … It acts on the presynaptic regulation of glutamate and shows strong neuroprotective properties.

  9. Drug

    Drinabant

    go.drugbank.com/drugs/DB05750
    Investigational

    It is currently developed in obesity and its associated comorbidities. AVE-1625 is also being developed for the treatment of Alzheimer disease. … AVE-1625 is an oral selective and potent antagonist of cannabinoid 1 (CB1) receptors having the same mechanism of action as rimonabant.

  10. Drug

    Caviar, unspecified

    go.drugbank.com/drugs/DB14241
    Approved

    Caviar, unspecified is an animal extract used in some OTC (over-the-counter) products. It is not an approved drug.